Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

The FDA is continuing its push to expedite early-stage research for drug developers and is now accepting applications for a new pilot program aimed at accelerating U.S. clinical trials. The primary ...

Job cuts continue to climb and pervade the biopharma sector this year, defying hopes that 2024 marked a peak. After shedding more than 14,000 jobs in all of 2024, the industry surpassed 13,000 layoffs ...